SCHEMBL185702

SCHEMBL185702

CC(C(=O)O)c1ccc(F)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 9/20 0.61
PTGS1 P23219 7/20 0.57
AKR1C3 P42330 5/20 0.57
CYP2C9 P11712 4/20 0.57
AKR1C2 P52895 4/20 0.57
LMNA P02545 3/20 0.57
CXCR1 P25024 2/20 0.57
CXCR2 P25025 2/20 0.57
SLC22A6 Q4U2R8 2/20 0.57
TSHR P16473 2/20 0.57
ALB P02768 1/20 0.57
ESR1 P03372 1/20 0.57
ALOX5 P09917 1/20 0.57
RARB P10826 1/20 0.57
ADRB3 P13945 1/20 0.57
NFKB1 P19838 1/20 0.57
HTR2A P28223 1/20 0.57
NR1I3 Q14994 1/20 0.57
CXCL8 P10145 1/20 0.57
BLM P54132 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4767889 1.00 PTGS2 (0.61) PTGS2PTGS1AKR1C3CYP2C9AKR1C2
SCHEMBL1711069 1.00 PTGS2 (0.61) PTGS2PTGS1AKR1C3CYP2C9AKR1C2
Hydrochloric Acid SCHEMBL9716491 0.98 PTGS2 (0.59) PTGS2PTGS1AKR1C3CYP2C9AKR1C2
SCHEMBL9592228 0.94 PTGS2 (0.71) PTGS2PTGS1AKR1C3CYP2C9AKR1C2
SCHEMBL59197 0.88 PTGS2 (0.74) PTGS2PTGS1AKR1C3CYP2C9AKR1C2
Fluorobenzene SCHEMBL28140330 0.87 PTGS2 (0.62) PTGS2PTGS1AKR1C3CYP2C9AKR1C2
SCHEMBL20029953 0.86 GRM7 (0.46) PTGS2PTGS1AKR1C3CYP2C9AKR1C2
SCHEMBL23003791 0.84 GRM7 (0.47) PTGS2LMNAKMT2AGRM7
SCHEMBL10443227 0.83 GRM7 (0.44) PTGS2PTGS1AKR1C3CYP2C9AKR1C2
SCHEMBL20130289 0.82 GRM7 (0.46) PTGS2LMNAKMT2AGRM7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 378 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3433239-B1 SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) 2026-05-27 EP disclosed
US-20260092074-A1 Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof GUANGZHOU VINNOCENT PHARMACEUTICAL LTD (CN) 2026-04-02 US disclosed
EP-4709725-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF Progentos Therapeutics, Inc. (US) 2026-03-18 EP disclosed
US-12565496-B2 Substituted 1H-pyrrolo[3,2-b]pyridine compounds and methods of use thereof BAYER AKTIENGESELLSCHAFT (DE) 2026-03-03 US disclosed
US-20250296971-A1 GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS 3B PHARMACEUTICALS GMBH (DE) 2025-09-25 US disclosed
US-20250281424-A1 SMALL MOLECULE ANTAGONISTS OF PF4 ZHOU YUHANG (US) 2025-09-11 US disclosed
US-20250276972-A1 COMPOUNDS AS CASEIN KINASE INHIBITORS GRITSCIENCE BIOPHARMACEUTICALS CO LTD (CN) 2025-09-04 US disclosed
EP-4574830-A1 ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF Guangzhou Vinnocent Pharmaceutical Limited (CN) 2025-06-25 EP disclosed
US-12331056-B2 SHP2 phosphatase inhibitors and methods of use thereof RELAY THERAPEUTICS, INC. (US) 2025-06-17 US disclosed
CN-120058445-A Method for generating aryl phenol compound by hydroxylation of uranium photocatalytic aryl fluorine compound and application of method 华东师范大学 2025-05-30 CN disclosed
WO-1995024424-A1 CYCLIC PEPTIDE LHRH ANTAGONISTS ABBOTT LABORATORIES (US) 1995-09-14 WO disclosed
WO-1995006046-A1 INDOLE DERIVATIVES AS THROMBOXANE A2 ANTAGONISTS PFIZER LIMITED (GB) 1995-03-02 WO disclosed
WO-1995004713-A1 2-AMINOINDANS AS SELECTIVE DOPAMINE D3 LIGANDS THE UPJOHN COMPANY (US) 1995-02-16 WO disclosed
US-5175294-A For treatment of bone disorders ADIR ET COMPAGNIE (FR) 1992-12-29 US disclosed
US-5061704-A PATHOLOGIES INVOLVING LOSS OF BONE TISSUE ADIR ET COMPAGNIE (FR) 1991-10-29 US disclosed
EP-0417454-A2 Reduced size LHRH analogs ABBOTT LABORATORIES (US) 1991-03-20 EP disclosed
EP-0386243-A1 PLATINUM (II) COMPLEXES SAGAMI CHEMICAL RESEARCH CENTER (JP) 1990-09-12 EP disclosed
CN-87100040-A The alkylamine that alkyl diaryl replaces, its preparation technology's method, the medicine of using and containing this compounds 1987-09-16 CN disclosed
EP-0048136-B1 PROCESS FOR PREPARING ALPHA-AROMATIC GROUP SUBSTITUTED ALKANOIC ACIDS OR ESTERS THEREOF SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) 1986-06-11 EP disclosed
US-4411975-A TONER AND DEVELOPER FOR ELECTROSTATIC IMAGES XEROX CORPORATION (US) 1983-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250296971-A1 GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS GIPR, VIP, GRPR PTGS2 2861/4885PTGS1 1329/4885AKR1C3 2421/4885
US-20250281424-A1 SMALL MOLECULE ANTAGONISTS OF PF4 PF4, F12, F2 PTGS2 1649/4885PTGS1 1209/4885AKR1C3 3414/4885
US-20260092074-A1 Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof STS, NR5A1, CYP21A2 PTGS2 1705/4885PTGS1 618/4885AKR1C3 130/4885
US-12331056-B2 SHP2 phosphatase inhibitors and methods of use thereof PTPRCAP, PTPN22, PTPN1 PTGS2 2733/4885PTGS1 2665/4885AKR1C3 4257/4885
US-12565496-B2 Substituted 1H-pyrrolo[3,2-b]pyridine compounds and methods of use thereof CYP1B1, CBR1, CYP4B1 PTGS2 2171/4885PTGS1 1164/4885AKR1C3 606/4885
US-20250276972-A1 COMPOUNDS AS CASEIN KINASE INHIBITORS PACSIN2, CSNK1A1, CSNK1G3 PTGS2 2515/4885PTGS1 2352/4885AKR1C3 3860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.